Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00198172
Status:
TERMINATED
Last Update Posted:
2014-06-03
First Post:
2005-09-08
Brief Title:
Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors
Sponsor:
Indiana University School of Medicine
Organization:
Indiana University
Study Overview
Official Title:
Phase II Study of Cisplatin Plus Epirubicin Salvage Chemotherapy in Refractory Germ Cell Tumors
Status:
TERMINATED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Accrual Goal Met
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study proposes to evaluate the combination of cisplatin plus epirubicin in patients with refractory germ cell tumor not amendable to cure with surgery or standard platinum salvage chemotherapy This regimen will be used in eligible patients after progression on ECOG Study E39897
Detailed Description:
To determine the feasibility and toxicity of combining epirubicin to fixed does cisplatin to determine the partial and complete response rate and duration of remission to determine the toxicity to ascertain the potential for greater than 12 month continuous disease-free survival and therefore potential curability
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None